E-Poster | Cardiology | Heart care

Top-line data show superiority of aficamten vs. beta-blocker for obstructive HCM

2025-05-31 - 2025-05

The positive phase 3 results of the MAPLE-HCM trial of aficamten vs. metoprolol for obstructive HCM were announced.
Results of a new SEQUOIA-HCM subanalysis were also announced.
Aficamten was associated with improved peak oxygen uptake and a tolerable safety profile vs. metoprolol, a beta-blocker, in patients with symptomatic obstructive hypertrophic cardiomyopathy, Cytokinetics reported.
The top-line results of the phase 3, multicenter, randomized, double-blind active-comparator MAPLE-HCM trial were announced in a company press release.

MedStar Health Spin-Out Auxira Health Offers Cardiology Practice Extension

2025-05-23 - 2025-05

Last week I wrote about Chicago-based Abundant Venture Partners’ announcement of a partnership with 17 health systems to build sustainable startup companies that benefit healthcare providers. One of those health systems is Maryland-based MedStar Health, and this week it rolled out the first startup developed through the collaboration, Auxira Health, which is focused on supporting cardiology practices.

Auxira pairs clinical support teams with cardiologists to increase care access for patients, improve clinician well-being and ensure financial sustainability. The company matches cardiology practices with dedicated clinical “pods”composed of advanced practice providers (APPs), medical assistants (MAs) and registered nurses (RNs) who work remotely as an extension of the cardiology team.

Regular cardiologist visits may significantly cut death risk for heart failure patients: Study

2025-05-19 - 2025-05

The study was conducted by researchers using French national medical records, focusing on patients diagnosed with heart failure within the previous five years as of January 2020. The data included detailed tracking of hospitalisations, treatments, and cardiology consultations.

“Heart failure can’t typically be cured, but with the right management, symptoms can be controlled for many years,” said Dr Guillaume Baudry of the Clinical Investigation Centre at Nancy University Hospital in France. “This research shows that regular follow-up with a cardiologist can make a measurable difference in outcomes.”

The team further analysed how different groups of patients fared, based on whether they had been hospitalised recently or were using diuretics—commonly prescribed medications that help remove excess fluid from the body.

Alarmingly, two out of every five patients went the entire year without seeing a cardiologist. These patients had notably worse outcomes, including higher risks of both death and hospitalisation.
For those recently hospitalised with heart failure, four annual cardiologist visits were found to be optimal, reducing the one-year risk of death from 34.3 per cent to 18.2 per cent.

Women with autoimmune disease face more death from heart disease than men

2025-05-16 - 2025-05

To better understand CVD mortality among people with underlying immune-mediated inflammatory diseases, Wassif and colleagues evaluated CVD deaths within the U.S. from 1999 to 2020 using data from the CDC Multiple Cause of Death files. Inflammatory diseases of interest included rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis.

Coimbatore hospital observes golden jubilee of Cardiology and Cardiothoracic surgery departments

2025-05-15 - 2025-05

The event was attended by Gopinath, Vice President of the KNC Trust, Aditya Krishna Pathy, Trustee of the KNC Trust, and Dr. Ragupathy Veluswamy, CEO of GKNM Hospital.
+A heart-shaped emblem that was unveiled represents the hospital’s dedication to delivering world-class cardiac care, including advanced interventions and life-saving surgeries.

MRI to identify cardiovascular disease ten years in advance

2025-05-14 - 2025-05

This is a very exciting and significant development,” said Professor Jill Belch, part of the School of Medicine’s Division of Cardiovascular Research, who led the study. “We looked at thousands of health records and it became apparent that the mass of the left ventricle was a clear indicator of future risk of cardiovascular disease. What made our findings particularly interesting was the difference we noted between men and women. In men, we found that a larger left ventricle, associated with heart attack and stroke, was linked to the diastolic - the bottom measure, - blood pressure. This level was what we would consider to be normal, albeit in the upper level. In women, we found a link between an increase in left ventricle mass and cholesterol. Again, this level was in the upper end of what we would consider normal. Both the level of blood pressure and cholesterol level were such that, normally, no preventative treatment would be offered.

Expert insights into the future of cardiology: What is the path forward

2025-05-13 - 2025-05

Cardiovascular care stands at a critical juncture marked by both clinical innovation and shifting healthcare paradigms. Tim Attebery and Tim Henry spoke on the key challenges and trends facing cardiovascular care, during a Philips-sponsored expert forum. Through Attebery's executive lens and Henry's clinical expertise, we can piece together a roadmap for the future of cardiology. Addressing these challenges head-on can pave the way for improved patient outcomes, more efficient care delivery, increased job satisfaction and a brighter overall future for cardiovascular care.

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

2025-05-09 - 2025-05

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

tudy shows no connection between PM2.5 spikes and major cardiovascular events

2025-05-08 - 2025-05

In a recent study published in the Journal of Cardiology, researchers examined the relationship between exposure to peak levels of particulate matter less than 2.5 µm (PM2.5) and the incidence of major adverse cardiovascular events (MACEs).

Cardiovascular disease (CVD) is the leading cause of death worldwide, with air pollution being a modifiable risk factor. PM2.5 is particularly harmful as it can enter the bloodstream, aggravate existing cardiovascular conditions, and contribute to stroke and myocardial infarction. Recent data suggest that air pollution is now the second largest mortality risk factor.

tudy shows no connection between PM2.5 spikes and major cardiovascular events

2025-05-08 - 2025-05

Outcomes in nonischemic cardiomyopathy vary by sex, type of implanted device

2025-05-07 - 2025-05

Rates of arrhythmic events and death remained common in patients indicated for implantable cardioverter defibrillator or cardiac resynchronization therapy despite adherence to optimal HF medical therapy, a speaker reported.
Overall, women and those implanted with a CRT device experienced lower risk for ventricular tachycardia (VT)/ventricular fibrillation (VF) or death in a population of patients with nonischemic cardiomyopathy.

Interventional Cardiology Frets Over Healthcare Policy Threats

2025-05-06 - 2025-05

WASHINGTON -- Interventional cardiologists expressed frustration and pessimism for their field, and healthcare in general, in a perceived climate of financial instability.

"It feels like a difficult time to be in healthcare and try to deliver exceptional care because of the financial pressures on the system," said new Society for Cardiovascular Angiography and Interventionsopens in a new tab or window (SCAI) president Srihari Naidu, MD, of New York Medical College and Westchester Medical Center in Valhalla, New York, in an interview.

Interventional Cardiology Frets Over Healthcare Policy Threats

2025-05-06 - 2025-05

‘A defining moment’: How cardiologists can get the most out of CT-guided PCI

2025-05-03 - 2025-05

In addition, artificial intelligence companies have started focusing more and more on the potential of CCTA, developing new software that can evaluate a patient’s imaging results and provide immediate recommendations related to the presence of high-risk plaques or other potentially harmful findings.

As this momentum has continued to grow, interventional cardiologists have also started turning to CCTA to plan ahead prior to PCI. This new document from SCAI and SCCT was created with this very practice in mind. By spreading the word about the benefits of this practice, the authors hopes to improve implementation and ensure specialists who do turn to CT-guided PCI are able to get the most value possible out of the experience.

SCAI Recognizes Members for Outstanding Service, Dedication

2025-05-02 - 2025-05

At the SCAI 2025 Scientific Sessions in Washington, DC, SCAI President James B. Hermiller, MD, MSCAI, recognized several individuals for their outstanding service, leadership, and contributions to patient care.
“These distinguished honorees have demonstrated an unparalleled commitment to advancing interventional cardiology, shaping the future of patient care, and strengthening our Society,” said SCAI President James B. Hermiller, MD, MSCAI. “Their contributions have left an indelible mark on the field, and we are proud to recognize their achievements.

Cardiology Electrodes Market Size, Share, and Growth Analysis

2025-04-30 - 2025-04

The global cardiology electrodes market has experienced a robust expansion in recent years, driven by the escalating prevalence of cardiovascular diseases (CVDs), which continue to be the leading cause of death worldwide. Early diagnosis and efficient monitoring of CVDs remain essential due to their status as the leading cause of global deaths according to the World Health Organization (WHO). Cardiac health assessment projects depend heavily on electrodes during electrocardiograms (ECGs) and stress tests and heart rate monitoring applications. The demand for these devices is soaring, especially with the rising number of patients seeking early detection and monitoring solutions. As cardiovascular conditions such as coronary artery disease, hypertension, and arrhythmias become more common, the need for high-quality cardiology electrodes to support diagnostic processes has increased significantly.

Apr 25, 2025 This Week in Cardiology Podcast

2025-04-29 - 2025-04

I chose cardiology because I was enamored by ECG reading. I read ECGs with the famous Charles Fisch. It was exhalating. To this day, the ECG helps me understand arrhythmias in the EP lab.

But ECG reading seems to have gone the way of auscultation. People seem to struggle with ECG reading. This has direct impact in the emergency department (ED), where missed ischemic changes can delay revascularization.
What I remain confused about is how artificial intelligence (AI) hasn't simply taken over the pattern recognition in an ECG.

SCAI 2025 to Feature Latest Clinical Innovations in Cardiology Care

2025-04-28 - 2025-04

This year's conference features more than ??500 faculty, 700 posters, 86 oral abstracts and more than 30 live cases assembling specialists in the field to analyze and discuss the latest in expertise, clinical data, and standard practice.

???“This year’s SCAI Scientific Sessions will be a dynamic, immersive experience that reflects the full breadth and future of interventional cardiology. We’ll explore how artificial intelligence and machine learning are being leveraged to improve efficiency and outcomes, highlight advances in structural heart interventions like TAVR, and address some of the most pressing challenges in our field,” said Binita Shah, MD, FSCAI, Program Chair for the 2025 SCAI Scientific Sessions. “In addition to state-of-the-art science, we’re also focusing on the well-being of the cardiovascular team—through dedicated programming on mental and physical health, radiation safety, and cath lab ergonomics. With hands-on learning labs, live cases, and first looks at the latest guidelines, the meeting is designed to equip attendees with both the technical insights and leadership tools to advance patient care and shape the future of our specialty.”

CardioOne Acquires CardioDiagnostics to Advance Innovation in Cardiology Care

2025-04-25 - 2025-04

DENVER, April 24, 2025 /PRNewswire/ -- CardioOne, a national growth and operational partner supporting independent cardiology practices, today announced the acquisition of CardioDiagnostics, an advanced cardiac monitoring platform. This acquisition marks a major strategic milestone, reinforcing CardioOne's commitment to providing cardiologists with state-of-the-art technology and robust support to ensure their practices thrive.

Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association

2025-04-23 - 2025-04

Critical care cardiology refers to the practice focus of and subspecialty training for the comprehensive management of life-threatening cardiovascular diseases and comorbid conditions that require advanced critical care in an intensive care unit. The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational structure, staffing, care delivery, and training paradigms lagged. The coronary care unit gradually evolved from a focus on rapid resuscitation from ventricular arrhythmias in acute myocardial infarction into a comprehensive cardiac intensive care unit designed to care for the sickest patients with cardiovascular disease. Over the past decade, the cardiac intensive care unit has continued to transform with an aging population, increased clinical acuity, burgeoning cardiac and noncardiac comorbidities, technologic advances in cardiovascular interventions, and increased use of temporary mechanical

Types of Heart Medications

2025-04-22 - 2025-04

Ask if there is a medication that costs less.
Talk to your doctor, pharmacist or other health care professional about your situation. They may know about programs that can help you get your medication for free or at a lower cost.
Check if the company that makes your medication offers patient assistance programs. Many drug companies have programs that provide medications if you are facing financial problems or are uninsured.
Look into government programs such as Medicaid or Medicare. They can help cover the cost of medications for eligible people.

The long con: How Narendra Yadav became Dr John Camm

2025-04-21 - 2025-04

His nine-page CV unfurled like a tapestry of triumphs — over 18,000 complex cardiology procedures and groundbreaking work in cutting-edge clinics from London to Nuremberg. He was Dr N John Camm, a cardiologist of international renown. Only, he wasn’t.For close to 12 years, Narendra Vikramaditya Yadav allegedly pulled off a stunning hoax by pretending to be Dr John Camm, a celebrated UK-based cardiologist and professor at the prestigious St George’s University in London. On April 7, the Madhya Pradesh Police arrested Dr Narendra Vikramaditya Yadav from Prayagraj in Uttar Pradesh on charges of forging his medical documents and performing surgeries and procedures without sanction.

rare heart surgery performed by kmc hospital

2025-04-19 - 2025-04

This complex coronary intervention was done by the cardiology team led by Dr Narasimha Pai, HoD of cardiology, and Dr Dithesh M, associate consultant, cardiology, at KMC Hospital, Dr BR Ambedkar Circle.
Dr Pai stated the patient was suggested an emergency coronary angiography after examination. It revealed a complete blockage (100% occlusion) in the proximal left anterior descending (LAD) artery, a major vessel that supplies blood to the heart. Initial treatment involved balloon angioplasty to restore blood flow and quickly stabilise his condition. However, further evaluation showed a severely calcified segment in the proximal to mid-LAD artery. This heavy calcification presented a significant obstacle to the successful delivery and optimal expansion of a stent, which is crucial for maintaining long-term blood flow and preventing future blockages, he explained.

Madhya Pradesh Hospital's Licence Suspended After 'Fake' Cardiologist Case

2025-04-17 - 2025-04

The Madhya Pradesh health department on Wednesday suspended the licence of Damoh-based Mission Hospital, where 'fake' cardiologist Narendra Yadav alias Narendra John Camm performed unauthorised surgeries on patients, an official said.Damoh district's Chief Medical and Health Officer (CMHO) Mukesh Jain said the hospital's licence expired on March 31, 2025, and its management had applied for renewal in December last year.
The application for renewal was returned to the management after some shortcomings were found in the hospital, he said.
Jain said the hospital was told to apply again within seven days after removing the shortcomings.

Bengaluru, Karnataka, 15th of April 2025 : At the 9th edition Shake Heart Annual Conference 2025, themed on Saving Deaths and Damages from Heart Attacks was held on April 13 in Dubai, interventional cardiologists and eminent heart surgeons provided a 360-

2025-04-16 - 2025-04

Bengaluru, Karnataka, 15th of April 2025 : At the 9th edition Shake Heart Annual Conference 2025, themed on Saving Deaths and Damages from Heart Attacks was held on April 13 in Dubai, interventional cardiologists and eminent heart surgeons provided a 360-degree perspective on incidence and management of cardiovascular disease. SHAKE is an acronym for Saving Heart Attacks-key Efforts and this year the conference highlighted different aspects including new pathbreaking treatment protocols adopted. Cardiology experts presented allied impact of heart disease such as cardiovascular metabolic kidney disease, heart disease in women and innovative AI-assisted precision medicine interventions among many other aspects.

Spanish Cardiologists Release Gender-Specific CV Guide

2025-04-14 - 2025-04

Cardiovascular ( CV) diseases are the leading cause of death among women, responsible for 35% of all female deaths globally, according to 2019 data. Alarmingly, myocardial infarction cases are rising among younger women. To address this, the Spanish Society of Cardiology’s (SEC’s) Working Group on Women and Cardiovascular Disease (SEC-GT CVD in Women) and the Association of Preventive Cardiology convened a multidisciplinary panel of experts from various Spanish societies and associations.

First 500 patients in Align-AR trial using TAVR for pure aortic regurgitation show strong outcomes

2025-04-11 - 2025-04

He said operators have used a lot of off-label commercially available TAVR devices, but these are designed for use in patients with a aortic stenosis (AS) with a heavily calcified aortic annulus to anchor the valve. The results in AR patients without calcium is less than ideal, Makkar said."We tend to have a high risk of complications, specifically valve migration or embolization, which can be about 10-15%. There also is a significant incidence of paravalvular leakage, which contributes to poor long-term outcomes," Makkar explained.
The JenaValve system is a self-expanding valve and features three leaflet-locating clips that anchor the valve securely by clipping the valve leaflets and without relying on calcification. This design provides a stable fit and significantly reduces the risk of valve migration or embolization—challenges common when using off-label devices for AR.
The Align-AR trial is looking at safety and efficacy. Data from the first 180 patients presented at TCT 2023 was submitted to the U.S. Food and Drug Administration (FDA) for review.

Explosion’ of incretin therapy use among new developments in cardiology

2025-04-10 - 2025-04

“We’re able to finally talk about truly evidence-based therapies that allow us to change the natural history for heart failure with preserved ejection fraction,” he explained. “We’re able to review about 50 years of information that emphatically demonstrate the progress we’ve made in reducing the risk of death and disability due to heart failure by at least 50% over the last several decades.”
Yancy also talked about improved knowledge about risk modification for conditions like hypertension and the “continued explosion of the use of the incretin therapies in the cardiovascular space.”We’re completely engaged, yet we understand we have to navigate the cost of therapy and the equation that is the difference between cost and value,” he added.

The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma

2025-04-09 - 2025-04

Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing myocardial ischaemia (a mismatch between myocardial blood supply and demand). However, this model, which focuses on diagnosing and managing coronary artery disease based on ischaemia and cardiovascular events, is flawed. By the time ischaemia manifests, it is often too late for optimal intervention, limiting the effectiveness of treatment options. Despite decades of medical advances, coronary artery disease continues to be a leading cause of morbidity and mortality globally, highlighting the inadequacy of this traditional ischaemia-centric model.
The Lancet home. Opens in new tab
FREE with registration!

Gujarat cardiologists threaten strike from Apr 1-7 demanding better PMJAY compensation

2025-04-04 - 2025-04

The cost of treatment has increased continuously over the last decade. However, the package rates have not increased accordingly, which is creating obstacles in providing quality treatment to patients, claim the cardiologist
The forum said, “The aim of PMJAY is to make healthcare accessible. But the rates decided by ignoring the economic realities are a hindrance. Insufficient increase in PCI (Percutaneous Coronary Intervention) and other packages is making it difficult to provide interventional cardiology services under PMJAY.”

Gujarat cardiologists threaten strike from Apr 1-7 demanding better PMJAY compensation

2025-04-04 - 2025-04

Bayer Pharma to expand cardiology, women’s health portfolios with new drugs this year

2025-04-02 - 2025-04

Bayer on Tuesday announced that it was preparing market launches this year of two new drugs from its cardiology and women’s health portfolios reportedly to strengthen its pharmaceuticals business amid a high debt burden.

The company maintained tat it has made significant investments in R&D to accelerate medical innovations and build a highly differentiated pipeline for long-term growth across key therapeutic areas, including oncology, cardiovascular diseases, neurology and rare diseases, and immunology.

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

2025-04-02 - 2025-04

The Tell-Tale Heart podcast host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP, was on the ground in Chicago, Illinois, for the 2025 American College of Cardiology Scientific Session. Beavers spoke with several presenters, researchers, and experts about the key data being discussed at the meeting.
The first guest of this episode, Glen Harrington, PharmD, FACC, FHFSA, BCCP, CPP, HFCert, discussed what the ACC meeting has to offer, specifically for pharmacists in all areas of expertise. As co-chair of the Pharmacists’ Work Group at ACC, Harrington focuses on supporting pharmacists involved in cardiology.

Dr. Christopher Kramer is New American College of Cardiology President

2025-03-31 - 2025-03

"I see significant challenges and opportunities for the field of cardiology in the coming years, including workforce issues, health equity, diversity and inclusion, and AI-driven solutions, that need to be addressed to achieve ACC's mission of transforming cardiovascular care for all," Kramer said. "I am looking forward to using my term as president to help ACC be a leader on these issues, while getting to know more of our inspiring, diverse membership and hearing their concerns and achievements across the U.S. and throughout the world."

Kramer, whose interest in cardiology began during a summer scholarship program in high school, received his medical degree from the University of California, San Francisco School of Medicine. He completed his residency and chief residency in internal medicine and fellowship in cardiology at the Hospital of the University of Pennsylvania in Philadelphia. His first faculty appointment was at Allegheny General Hospital in Pittsburgh, then MCP/Hahnemann University School of Medicine in Philadelphia, where he directed the cardiology fellowship before moving in 1999 to the University of Virginia School of Medicine in Charlottesville, Virginia, where he became chief of

How 2 new Miami Tech endeavors aim ‘to bring the heartbeat back’

2025-03-31 - 2025-03

When Chris Daniels shared on Linkedin that he has joined The LAB Miami as General Manager and he is partnering with Erick Gavin to create and run a full-cycle entrepreneurship program called Reefside Ventures in Miami, he described it best: It’s a “full-circle moment” in his 10-year journey to help accelerate Miami’s rise as a global tech hub.

Daniels most recently helped create and run, with Gavin, the Built In Miami program as part of Venture Miami, and earlier founded and ran the Shrimp Society to engage founders and young professionals at the earliest stages. He also has worked at startups and dabbled in angel investing. It all started a decade ago in Daniels’ days as a “startup junkie” while studying at University Miami. He would spend evenings at tech events at The LAB Miami, one of Miami tech’s pioneers, to experience and be part of “the real startup world.”

GE HealthCare Introduces Measures to Improve Cardiac Care Pathway

2025-03-28 - 2025-03

GE HealthCare today announced the U.S. launch of its Flyrcado (flurpiridaz F 18) injection. The company made the announcement as it prepares to showcase new artificial intelligence (AI)-powered innovations at the 2025 American College of Cardiology (ACC) Annual Scientific Session and Expo (March 29-31), reflecting its strategy to leverage AI to help increase efficiency and enable seamless data integration across the cardiology care pathway.
GE HealthCare has been investing in AI for many years and has topped the U.S. Food and Drug Administration (FDA) list of AI-enabled device authorizations for three consecutive years with 85 authorizations.i

Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling

2025-03-27 - 2025-03

High circulating levels of ceramides, particularly long-chain ceramides, are an independent risk factor for atherosclerotic cardiovascular disease, but the mechanisms by which circulating ceramides might drive atherosclerosis development and progression are not well understood. A study published in Nature has identified two transmembrane G protein-coupled receptors (GPCRs) that mediate extracellular-to-intracellular ceramide signalling and shows that this signalling axis triggers activation of the NLRP3 inflammasome in endothelial cells and macrophages. Moreover, blocking these receptors alleviates the atherosclerosis that is induced by a high-fat diet or aggravated by chronic kidney disease (CKD) in mice. “These findings establish a mechanistic framework for the pro-atherogenic effects of ceramides and uncover therapeutic opportunities targeting ceramide signalling, offering innovative strategies beyond conventional lipid-lowering approaches,” highlights Wei Kong, lead investigator of the study.

Mount Sinai Cardiologists Present Late Breaking Trials and Breakthrough Studies at American College of Cardiology Scientific Sessions (ACC.25)

2025-03-26 - 2025-03

Top experts from Mount Sinai Fuster Heart Hospital in New York City will present late breaking trials and other landmark studies at ACC.25 taking place March 29-31 in Chicago. I have included details on their notable presentations below. We have two late-breaking clinical trials, and research on AI as it relates to the field of cardiology care. Please let me know if need to coordinate interviews involving their work. Our experts are also available to comment on trending topics, and outside studies.

Webinar on Cardiology and Cardio Care

Top-line data show superiority of aficamten vs. beta-blocker for obstructive HCM

MedStar Health Spin-Out Auxira Health Offers Cardiology Practice Extension

Regular cardiologist visits may significantly cut death risk for heart failure patients: Study

Women with autoimmune disease face more death from heart disease than men

Coimbatore hospital observes golden jubilee of Cardiology and Cardiothoracic surgery departments

MRI to identify cardiovascular disease ten years in advance

Expert insights into the future of cardiology: What is the path forward

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

tudy shows no connection between PM2.5 spikes and major cardiovascular events

tudy shows no connection between PM2.5 spikes and major cardiovascular events

Outcomes in nonischemic cardiomyopathy vary by sex, type of implanted device

Interventional Cardiology Frets Over Healthcare Policy Threats

Interventional Cardiology Frets Over Healthcare Policy Threats

‘A defining moment’: How cardiologists can get the most out of CT-guided PCI

SCAI Recognizes Members for Outstanding Service, Dedication

Cardiology Electrodes Market Size, Share, and Growth Analysis

Apr 25, 2025 This Week in Cardiology Podcast

SCAI 2025 to Feature Latest Clinical Innovations in Cardiology Care

CardioOne Acquires CardioDiagnostics to Advance Innovation in Cardiology Care

Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association

Types of Heart Medications

The long con: How Narendra Yadav became Dr John Camm

rare heart surgery performed by kmc hospital

Madhya Pradesh Hospital's Licence Suspended After 'Fake' Cardiologist Case

Bengaluru, Karnataka, 15th of April 2025 : At the 9th edition Shake Heart Annual Conference 2025, themed on Saving Deaths and Damages from Heart Attacks was held on April 13 in Dubai, interventional cardiologists and eminent heart surgeons provided a 360-

Spanish Cardiologists Release Gender-Specific CV Guide

First 500 patients in Align-AR trial using TAVR for pure aortic regurgitation show strong outcomes

Explosion’ of incretin therapy use among new developments in cardiology

The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma

Gujarat cardiologists threaten strike from Apr 1-7 demanding better PMJAY compensation

Gujarat cardiologists threaten strike from Apr 1-7 demanding better PMJAY compensation

Bayer Pharma to expand cardiology, women’s health portfolios with new drugs this year

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

Dr. Christopher Kramer is New American College of Cardiology President

How 2 new Miami Tech endeavors aim ‘to bring the heartbeat back’

GE HealthCare Introduces Measures to Improve Cardiac Care Pathway

Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling

Mount Sinai Cardiologists Present Late Breaking Trials and Breakthrough Studies at American College of Cardiology Scientific Sessions (ACC.25)

cardiocare@confmeets.net

support@confmeets.net

+44-7477-467410